NLS Pharmaceutics (NASDAQ:NCEL) Trading Up 3.2% – Still a Buy?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL)’s stock price was up 3.2% on Thursday . The stock traded as high as $3.39 and last traded at $3.27. Approximately 17,891 shares traded hands during trading, a decline of 72% from the average daily volume of 62,883 shares. The stock had previously closed at $3.17.

NLS Pharmaceutics Stock Performance

The firm has a 50-day moving average price of $3.13 and a two-hundred day moving average price of $2.89.

Insider Activity

In other news, Director Michel Revel bought 54,545 shares of NLS Pharmaceutics stock in a transaction on Monday, April 27th. The stock was acquired at an average cost of $2.75 per share, for a total transaction of $149,998.75. Following the completion of the acquisition, the director owned 957,530 shares of the company’s stock, valued at $2,633,207.50. This trade represents a 6.04% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Olivier Samuel bought 81,818 shares of NLS Pharmaceutics stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $2.75 per share, with a total value of $224,999.50. Following the completion of the acquisition, the director directly owned 81,818 shares of the company’s stock, valued at $224,999.50. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 16.40% of the company’s stock.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.